Education
About Us
Working with TipRanks
Follow Us
Invex Therapeutics Ltd. (AU:IXC)
:IXC
RESEARCH TOOLSreports
Total Valuation
Invex Therapeutics Ltd. has a market cap or net worth of AU$6.69M. The enterprise value is ―.
Market CapAU$6.69M
Enterprise Value―
Share Statistics
Invex Therapeutics Ltd. has 75,153,850 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding75,153,850
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Invex Therapeutics Ltd.’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -21.58%.
Return on Equity (ROE)-0.29
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-21.58%
Return on Capital Employed (ROCE)-0.38
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover0.20
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Invex Therapeutics Ltd. is -2.75. Invex Therapeutics Ltd.’s PEG ratio is 0.50.
PE Ratio-2.75
PS Ratio0.00
PB Ratio1.13
Price to Fair Value0.79
Price to FCF-16.32
Price to Operating Cash Flow-16.47
PEG Ratio0.50
Income Statement
In the last 12 months, Invex Therapeutics Ltd. had revenue of 1.21M and earned -1.64M in profits. Earnings per share was -0.02.
Revenue1.21M
Gross Profit1.21M
Operating Income-2.13M
Pretax Income-2.85M
Net Income-1.64M
EBITDA-720.44K
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -368.36K and capital expenditures 0.00, giving a free cash flow of -368.36K billion.
Operating Cash Flow-368.36K
Free Cash Flow-368.36K
Free Cash Flow per Share>-0.01
Dividends & Yields
Invex Therapeutics Ltd. pays an annual dividend of AU$0.186, resulting in a dividend yield of ―
Dividend Per ShareAU$0.186
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.49
52-Week Price Change50.00%
50-Day Moving Average0.09
200-Day Moving Average0.08
Relative Strength Index (RSI)55.24
Average Volume (3m)30.74K
Important Dates
Invex Therapeutics Ltd. upcoming earnings date is Aug 22, 2025, TBA (Not Confirmed).
Last Earnings DateFeb 6, 2025
Next Earnings DateAug 22, 2025
Ex-Dividend DateDec 08, 2023
Financial Position
Invex Therapeutics Ltd. as a current ratio of 14.18, with Debt / Equity ratio of 0.00%
Current Ratio14.18
Quick Ratio14.18
Debt to Market Cap0.00
Net Debt to EBITDA8.36
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Invex Therapeutics Ltd. has paid -1.21M in taxes.
Income Tax-1.21M
Effective Tax Rate0.42
Enterprise Valuation
Invex Therapeutics Ltd. EV to EBITDA ratio is 2.09, with an EV/FCF ratio of 0.62.
EV to Sales-1.24
EV to EBITDA2.09
EV to Free Cash Flow0.62
EV to Operating Cash Flow0.62
Balance Sheet
Invex Therapeutics Ltd. has AU$5.81M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of -AU$5.81M billion.
Cash & Marketable SecuritiesAU$5.81M
Total DebtAU$0.00
Net Cash-AU$5.81M
Net Cash Per Share-AU$0.08
Tangible Book Value Per ShareAU$0.08
Margins
Gross margin is 100.00%, with operating margin of -176.00%, and net profit margin of -135.43%.
Gross Margin100.00%
Operating Margin-176.00%
Pretax Margin-235.43%
Net Profit Margin-135.43%
EBITDA Margin-59.43%
EBIT Margin-235.43%
Analyst Forecast
The average price target for Invex Therapeutics Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―